Federal Register of Legislation - Australian Government

Primary content

PB 40 of 2014 Arrangements as made
This instrument amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (No. PB 116 of 2010) to delete the brand Imulate for the drug Mycophenolic Acid in the forms Capsule containing mycophenolate mofetil 250 mg and Tablet containing mycophenolate mofetil 500 mg, and make amendments to the restriction text for the drug Plerixafor.
Administered by: Health
Made 15 May 2014
Registered 21 May 2014
Tabled HR 26 May 2014
Tabled Senate 16 Jun 2014
Date of repeal 02 Jun 2014
Repealed by Division 1 of Part 5A of the Legislative Instruments Act 2003

 

PB 40 of 2014

National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No. 5)

 

National Health Act 1953

___________________________________________________________________________

 

 

I, KIM BESSELL, Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Amendment Instrument under subsections 100(1) and 100(2) of the National Health Act 1953.

Dated   15 May 2014

 

 

 

 

 

 

 

 

 

 

 

 

 

 

KIM BESSELL

Assistant Secretary

Pharmaceutical Access Branch

Pharmaceutical Benefits Division

Department of Health

___________________________________________________________________________

 

 


1       Name of Instrument

 

(1)                This Instrument is the National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No.5).

 

(2)                This Instrument may also be cited as PB 40 of 2014.

 

2              Commencement

This Instrument commences on 1 June 2014.

3              Amendments to PB 116 of 2010

Schedule 1 amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (PB 116 of 2010).

 

 


Schedule 1       Amendments

[1]           Schedule 1, entry for Mycophenolic Acid, in the form Capsule containing mycophenolate mofetil 250 mg, brand name Imulate

omit

[2]           Schedule 1, entry for Mycophenolic Acid, in the form Tablet containing mycophenolate mofetil 500 mg, brand name Imulate

omit

[3]           Schedule 3, entry for Plerixafor [Circumstances Code: 4549]

omit from the column headed “Circumstances and Purposes”:

Patient must be undergoing chemotherapy plus G-CSF mobilisation and their peripheral blood CD34+ count is less than 10,000 per microlitre on the day of planned collection; OR

substitute:

Patient must be undergoing chemotherapy plus G-CSF mobilisation and their peripheral blood CD34+ count is less than 10,000 per millilitre or less than 10 million per litre on the day of planned collection; OR

[4]           Schedule 3, entry for Plerixafor [Circumstances Code: 4550]

omit from the column headed “Circumstances and Purposes”:

Patient must be undergoing chemotherapy plus G-CSF mobilisation and their peripheral blood CD34+ count is less than 10,000 per microlitre on the day of planned collection; OR

substitute:

Patient must be undergoing chemotherapy plus G-CSF mobilisation and their peripheral blood CD34+ count is less than 10,000 per millilitre or less than 10 million per litre on the day of planned collection; OR